China News Service, June 10. According to the website of the State Food and Drug Administration, the State Food and Drug Administration recently issued the "Notice on 16 Batches of Drugs Not Complying with the Regulations (No. 36 of 2021)" (hereinafter referred to as the "Notice").

The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co., Ltd. were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection Institute. .

The relevant situation is now announced as follows:

  After inspection by Anhui Food and Drug Inspection and Research Institute, it was labeled as 1 batch of compound clotrimazole cream produced by Hebei Jiuzheng Pharmaceutical Co., Ltd. which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co., Ltd. One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity.

  After inspection by Shanxi Provincial Food and Drug Inspection Institute, it is indicated that the entrusting party is Shanxi Tianzhi Pharmaceutical Co., Ltd. and the trustee is Chongqing Tianzhi Pharmaceutical Co., Ltd. The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture .

  The three batches of joint pain relief ointment produced by Jiangsu Baiyi Pharmaceutical Co., Ltd. and Jiangxi Ji’an Sanli Pharmaceutical Co., Ltd. were inspected by Yunnan Food and Drug Inspection and Research Institute and were not in compliance with the regulations, and the items that did not meet the regulations were content determination.

  A batch of Huanglian Shangqing Pills produced by Sichuan Qiyun Pharmaceutical Co., Ltd. was not compliant with the regulations after inspection by the Hunan Provincial Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center), and the non-compliant items are the difference in filling quantity.

  After inspection by the Tibet Autonomous Region Food and Drug Inspection and Research Institute, a batch of Keteling Capsules produced by Yili Pharmaceutical Co., Ltd. was not in compliance with the regulations, and the non-compliance items were microbiological limits.

  After inspection by Wuhan Institute of Drug and Medical Device Inspection, it was marked that a batch of Jiawei Huoxiang Zhengqi Pills produced by Guangzhou Yuehua Pharmaceutical Co., Ltd. did not meet the requirements, and the items that did not meet the requirements were identified.

  After inspection by China Food and Drug Control Institute, the three batches of argentea produced by Anhui Jiancheng Chinese Medicine Decoction Pieces Co., Ltd., Anhui Xintai Pharmaceutical Co., Ltd., and Chengdu Ji'ankang Pharmaceutical Co., Ltd. did not meet the requirements and did not meet the requirements. For traits.

  According to the inspection by Gansu Provincial Institute of Drug Inspection, the 2 batches of Bupleurum spp. produced by Chongqing Zhongmiao Pharmaceutical Co., Ltd. are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co. The second Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; the 1 batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co., Ltd. does not meet the requirements, and the items that do not meet the requirements are impurities .

  The "Notice" stated that for the above-mentioned non-compliant drugs, the drug supervision and administration department has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recalls, and investigations into the reasons for non-compliance and effective rectification.

  The State Drug Administration requires relevant provincial drug regulatory authorities to organize investigations into the illegal activities of the above-mentioned enterprises and units producing and selling counterfeit and inferior drugs in accordance with the Drug Administration Law of the People's Republic of China, and to disclose the results of investigations in accordance with regulations.